Catalyst Pharmaceutical Partners Announces Recommendation of Data Monitoring Committee for Pivotal Phase lll Clinical Trial for Firdapse(TM)

Wed Mar 27, 2013 8:03am EDT

* Reuters is not responsible for the content in this press release.

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130327:nGNXUXLBIa

CORAL GABLES, Fla., March 27, 2013 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc.
(Nasdaq:CPRX), a specialty pharmaceutical company focused on the development and commercialization
of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases and
disorders, announced today that, on March 25, 2013, the independent Data Monitoring Committee
(DMC) overseeing the Company's ongoing pivotal Phase III clinical trial in the United States and
Europe evaluating Firdapse for the treatment of Lambert-Easton Myasthenic Syndrome (LEMS)
recommended that the Company continue the trial as planned based on the committee's review of
safety and clinical data from the trial.

The DMC is a group of experts responsible for the independent review of accumulated clinical
safety and efficacy data obtained in our clinical trial, in order to safeguard the interests and
safety of participants and future patients. The DMC considers study-specific data, as well as
relevant background knowledge about the disease, test agent or patient population under study.

The Firdapse Phase III clinical trial is designed as a randomized, double-blind,
placebo-controlled, discontinuation trial enrolling 30 patients diagnosed with LEMS at sites in
the U.S. and Europe. Catalyst anticipates that it will be adding up to 20 additional sites in the
U.S., Europe, Canada and South America. Catalyst expects to complete enrollment in the trial by
the end of the fourth quarter of 2013 and to announce top line data from the trial during the
second quarter of 2014.

About LEMS

Lambert-Eaton Myasthenic Syndrome, or LEMS, is a rare autoimmune disorder characterized by muscle
weakness of the limbs. The disease is caused by an autoimmune reaction where antibodies are formed
against the connection between nerves and the muscles they supply. Often, LEMS is associated with
an underlying malignancy, most commonly small-cell lung cancer, and in some individuals, LEMS is
the first symptom of such malignancy. LEMS generally affects the extremities, especially the legs.
As the disease most affects the parts of limbs closest to the trunk, difficulties with climbing
stairs or rising from a sitting position are commonly noted. Physical exercise and high
temperatures tend to worsen the symptoms. Other symptoms occasionally seen include weakness of the
muscles of the mouth, throat, and eyes. Individuals affected with LEMS also may have a disruption
of the autonomic nervous system, including dry mouth, constipation, blurred vision, impaired
sweating, and/or hypotension.

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners, Inc., is a specialty pharmaceutical company focused on the
development and commercialization of prescription drugs targeting rare (orphan) neuromuscular and
neurological diseases and disorders, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile
spasms, and Tourette's Syndrome. Catalyst's lead candidate, Firdapse for the treatment of LEMS, is
currently undergoing testing in a global, multi-center, pivotal phase III trial. Catalyst is also
developing a potentially safer and more potent vigabatrin analog (designated CPP-115) to treat
infantile spasms, and epilepsy, as well as other neurological conditions associated with reduced
GABAergic signaling, like post-traumatic stress disorder, Tourette's Syndrome, and movement
disorders associated with the treatment of Parkinson's Disease.

Forward-Looking Statements 

This press release contains forward-looking statements. Forward-looking statements involve known
and unknown risks and uncertainties, which may cause the Company's actual results in future
periods to differ materially from forecasted results. A number of factors, including whether the
Phase III trial will be successful, the Phase III trial will be completed in the schedule
described above, any of the Company's product candidates will ever be approved for
commercialization, as well as those factors described in the Company's filings with the U.S.
Securities and Exchange Commission (SEC), could adversely affect the Company. Copies of the
Company's filings with the SEC are available from the SEC, may be found on the Company's website
or may be obtained upon request from the Company. The Company does not undertake any obligation to
update the information contained herein, which speaks only as of this date.

CONTACT: Patrick J. McEnany
         Catalyst Pharmaceutical Partners
         Chief Executive Officer
         (305) 529-2522
         pmcenany@catalystpharma.com
         
         Melody Carey
         Rx Communications Group
         Co-President
         (917) 322-2571
         mcarey@rxir.com

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.